Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe.
Katharina VerlegerJohn R PenrodMelinda Manley DaumontCaitlyn T SolemLinlin LuoCynthia MacahiligNadine HertelPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
In the era pre-immunotherapy, HCRU and costs were substantial in aNSCLC 2L+ patients, with most of the costs accrued prior to start of 2L. NSQ patients incurred significantly higher total costs than SQ patients in all participating countries.